Q1 Earnings Estimate for REGENXBIO Issued By Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of REGENXBIO in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar expects that the biotechnology company will post earnings of $0.65 per share for the quarter. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s Q3 2025 earnings at $2.03 EPS and Q4 2025 earnings at ($1.44) EPS.

Several other equities analysts also recently commented on RGNX. The Goldman Sachs Group downgraded shares of REGENXBIO from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday, March 20th. Raymond James initiated coverage on REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price objective for the company. Morgan Stanley boosted their target price on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, March 14th. Finally, HC Wainwright dropped their price target on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.88.

REGENXBIO Price Performance

RGNX stock opened at $6.16 on Thursday. REGENXBIO has a 1-year low of $5.04 and a 1-year high of $17.99. The business has a 50 day simple moving average of $6.88 and a two-hundred day simple moving average of $8.22. The company has a market capitalization of $308.72 million, a price-to-earnings ratio of -1.22 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.

Hedge Funds Weigh In On REGENXBIO

Several large investors have recently modified their holdings of RGNX. FMR LLC boosted its stake in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the period. Stifel Financial Corp boosted its stake in shares of REGENXBIO by 13.3% during the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after purchasing an additional 17,563 shares during the period. Barclays PLC grew its holdings in REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after purchasing an additional 67,948 shares during the last quarter. Geode Capital Management LLC raised its position in REGENXBIO by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock worth $11,422,000 after purchasing an additional 44,037 shares during the period. Finally, GAMMA Investing LLC lifted its stake in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.